How GM-CSF inhalation improves clinical and biological factors in pulmonary alveolar proteinosis?

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461153
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Niigata University
• Principal Investigator: Tazawa Ryushi 新潟大学, 医歯学総合病院, 准教授 (70301041)
• Co-Investigator(Kenkyū-buntansha): Nakata Koh 新潟大学, 医歯学総合病院, 教授 (80207802) ; Ishii Haruyuki 杏林大学, 医学部呼吸器内科, 准教授 (30406970)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 肺胞蛋白症 / GM-CSF / 抗GM-CSF抗体 / 気管支肺胞洗浄液

Outline of Final Research Achievements

In this study, we approached therapeutic mechanisms of GM-CSF inhalation, a novel therapy for autoimmune pulmonary alveolar proteinosis. The studies on CT images of the patients, who underwent GM-CSF inhalation therapy, revealed that including intensity of the opacities to CT grading was useful for evaluating therapeutic response, suggesting improvement of intensity rather than extent of the opacities of more importance. Follow-up observation of the patients demonstrated that baseline %VC might be a prognostic factor for disease recurrence. Reduction of VC might be due to accumulation of surfactant-derived materials in the alveolar space, while fibrotic changes were not remarkable in the CT images of the patients. Notably, the CT grading also had significant correlation with serum markers such as SP-D and KL-6. Comparison of recombinant human GM-CSF derived from cells of three species revealed that sialylated oligosaccharide moieties prolong the bioactivity of rhGM-CSF in vitro.

Free Research Field

呼吸器内科学